FTAI Aviation Ltd vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? FTAI Aviation Ltd trades at $169.74 (market cap $17.57B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.8 (market cap $6.04B). The key difference: FTAI Aviation Ltd is far larger — about 2.9× Iovance Biotherapeutics Inc. Common Stock's market cap, and FTAI Aviation Ltd pays a 1.17% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 22 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| FTAI | IOVA | |
|---|---|---|
Market Cap | $17.57B | $6.04B |
Volume | 1,905,014 | 14,805,993 |
Sector | Industrials | Health |
52-Week High | $310.04 | $14.82 |
52-Week Low | $152.80 | $1.81 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $20.69B | $5.97B |
Dividend Yield | 1.17% | — |
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation Ltd. (FTAI) trades at $169.13, down 3.26% over 24 hours, with a bearish technical signal from moving averages. Recent financials show strong revenue growth to $2.51B in 2025 and a net income margin of 15.94%, but earnings have missed expectations for three consecutive quarters. The company announced a $500 million share repurchase program and a strategic aircraft acquisition, signaling management confidence. Valuation ratios are elevated, with a P/E of 37.35 and P/B of 43.49, reflecting high growth expectations.
The outlook for FTAI is mixed; analyst consensus is unanimously bullish with a $321.25 price target, but near-term risks include earnings misses and negative operating cash flow. Long-term growth drivers include expansion in aerospace products and power segments, though execution risks and market volatility could pressure the stock. Investors should weigh strong institutional support against fundamental headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →